Altamira Therapeutics Ltd CYTOF

Healthcare Biotechnology

Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing ribonucleic acid (RNA)-based therapeutics for extrahepatic targets (OligoPhore/SemaPhore delivery platforms). The Company has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery platform is also suited for messenger RNA (mRNA) and other types of RNA therapeutics and is focused to be leveraged via out-licensing to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. Like AM-401, the drug product is based on its OligoPhore technology.

OTCQB:CYTOF - Post by User

Altamira Therapeutics Ltd > CYTO.....This is what I'm thinking now...FWIW ; )

<< Previous

Bullboard Posts

Next >>

Comment by Iseneschalon Mar 25, 2024 1:41pm

41 Views

Post# 35951173

RE:RE:CYTO.....This is what I'm thinking now...FWIW ; )

And like I said....don't expect too much ; )

Now looking at "the big picture".......almost 60 million shares have traded and all you get is a paltry 58 cent profit????

Whats wrong with this picture?????

<< Previous

Bullboard Posts

Next >>

Abcourt Mines launches Flordin property drill campaign